Rapport Therapeutics CFO Troy A. Ignelzi reports purchase of $143,550 in common shares
RAPP•Rapport Therapeutics CFO Troy A. Ignelzi purchased 5,500 shares at $26.10 each, increasing his directly owned holdings to 15,500 shares.
1. CFO share purchase
Troy A. Ignelzi, chief financial officer of Rapport Therapeutics, purchased 5,500 common shares at $26.10 per share. The purchase increased his directly owned holdings to 15,500 shares.
